










The new Sars-Cov-2 (COVID-19) is causing thousands of deaths worldwide and has caused a 
global pandemic, one of the biggest health challenges ever faced in history. in the most severe cases, 
Sars-Cov-2 infection can cause fatal lung injuries. In this context, it is essential to recognise 
effective therapeutic agents against the virus. There are currently no direct and effective vaccines 
and antivirals available. People with pre-existing conditions, such as diabetes, and with chronic 
drug therapies in place may represent complex patients difficult to manage clinically during 
COVID-19 infection and at high risk of major complications. The regulation of blood glucose and 
the adoption of appropriate measures are critical aspects to consider for the diabetic patient in this 
pandemic period, especially in the patient with ongoing infection. In this article we describe the 
current evidence in the literature on the possible risks of side effects caused by taking antidiabetic 
drugs in the COVID-19 patient and the data on extra homeostasis glycemic activity useful to fight 
viral infection. 
 






The viral infection caused by the new Sars-Cov-2 (COVID-19), recorded its first cases in China at 
the end of 2019, and within a few months it became a global pandemic. At the time of writing this 
report, there were about 4.71 million infected cases and 315,000 deaths with over 250 countries 
affected. (1) COVID-19 infection can occur in several stages, the first with mild or asymptomatic 
symptoms and the second and third stages more severe, consisting of a generalized hyperactive 
inflammatory state caused by a cytokinic storm, which can cause fatal lung injury and multi-organ 
dysfunction that can quickly lead to death. Patients with pre-existing chronic diseases such as 
diabetes are at high risk of infection and increased complications, and the management of 
polypharmacy is complex, consisting of therapeutic agents that must treat the disease already 
present and agents against COVID-19 infection. To date, there are no direct antivirals and effective 




Clinical pharmacological aspects of the diabetic patient during the COVID-19 infection  
  
The Risks of anti-diabetes agents during SARS-COV-2 infection 
 
 
Continuous control and monitoring of blood glucose is of paramount importance for the diabetic 
patient, even more so during an ongoing COVID-19 infection. Currently, guidelines recommend 
diabetic patients to continue taking routine antidiabetic therapies, and to date there is no evidence 
that any therapeutic agent against diabetes can increase the risk of COVID-19 infection. Although 
the patient with diabetes is affected by Sars-Cov-2, blood glucose levels should continue to be 
monitored and blood glucose levels controlled with drug therapy. In a COVID-19 patient with Sars-
  
Cov-2 infection, and especially in more severe cases, a possible change in dosage, a therapeutic 
change, or even a discontinuation of the antidiabetes drug could be considered, but one should 
always consider the case individually depending on the clinical conditions. The most important 
factors to consider are glycemic normalization and the risk of hypoglycemia/hyperglycemia and the 
interactions between antidiabetic drugs and drugs used to fight COVID-19 infection. Diabetes 
therapy in a patient with COVID-19 infection could pose a serious risk of causing serious 
complications if poorly managed.  Metformin is among the first-line drugs for type 2 diabetes and is 
predominantly eliminated in the kidney, in a patient with COVID-19 renal function should be 
closely monitored to avoid the risk of lactic acidosis caused by increased drug concentration. (3) In 
addition, some antivirals used to fight COVID-19 are inhibitors of organic cation carrier OCT, 
metformin is a substrate of this protein, inhibiting OCT the concentrations of metformin in plasma 
may be higher with risk of lactic acidosis. Peptide-1 glucagon receptor agonist therapy (GLP-1RA) 
should probably be discontinued in patients with severe hemodynamic instability (compromising 
absorption from subcutaneous sites), renal dysfunction and gastrointestinal dysfunction. GLP-1RA 
may cause a delay in gastric emptying that leads to significant reductions in the rate and degree of 
absorption of certain oral drugs administered simultaneously such as darunavir or remdesivir 
antivirals. (4) Common side effects of GLP-1RA include nausea, vomiting and diarrhoea, which in 
a COVID-19 patient with similar gastrointestinal symptoms may lead to loss of electrolytes and risk 
of cardiac arrhythmias.  
Dipeptidil peptidase-4 (DPP4) inhibitors are associated with a low risk of hypoglycemia and are 
relatively safe in a wide range of renal function, probably this class of drugs can be considered the 
safest in a COVID-19 patient (5). The use of SGLT-2 inhibitors is more complex in COVID-19 
patients due to the risk of diabetic ketoacidosis, which can lead to potentially fatal cases. (6) The 
clinical condition of the patient, high concentration of ketone bodies, renal dysfunction are aspects 
to be considered for a possible interruption of treatment with SGLT-2. In patients with COVID-19 
on sulphoniluree therapy, a change in insulin therapy should be considered due to the risk of high 
hypoglycaemia in patients with Sars-Cov-2 infection. Caution with sulfonylureas should also be 
exercised in consideration of chloroquine, due to the risk of hypoglycaemia with both and if renal 
dysfunction is present. (7) 
The use of thiazolidinediones should be carefully evaluated in a hemodynamically unstable patient 
with liver dysfunction due to the risk of water retention and edema.  Insulin use probably requires 
dose modification in a COVID-19 patient, the most serious risk is hypoglycemia, but is probably 
preferable to the use of sulfonylureas and thiazolidinediones. 
 
The advantages of diabetes agents against SARS-COV-2 infection 
  
Normalization of glycemic homeostasis should be carefully performed with routine therapeutic 
agents, even during the COVID-19 infection phase. However, some evidence has shown that some 
antidiabetic drugs in COVID-19-like epidemics, such as SARS-COV and MERS, have been 
effective in combating viral infection.  It is now known that in the most severe stages of COVID-19 
infection an overactive and uncontrolled inflammatory system caused by a cytokinic cascade is 
responsible for multi-organ dysfunction and fatal lung lesions. In particular, the use of metformin 
has shown a decrease in inflammatory markers in patients with SARS-COV and MERS, however 
there is no clinical data to support this and its use in patients with severe COVID-19 should be 
carefully assessed in light of the risks described above.  (8) (9) The use of DPP IV inhibitors is 
being investigated in patients with COVID-19. The DPP4 protein is expressed in many cells 
including alveolar epithelium and inflammatory cells. MERS-CoV uses DPP4 to enter host cells 
(10), but it is not yet known whether Sars-Cov-2 uses the same vector to enter the cell as ACE-2. If 
this is demonstrated, the use of DPP IV inhibitors could reduce the risk of Sars-Cov-2 infection, but 
so far this has not been demonstrated and there are no clinical data to support it. (11) Similarly to 
metformin, the effects of reducing inflammatory markers are also known for GLP-1RA and have 
also demonstrated potential therapeutic benefit in patients with diabetes and acute lung injury (12). 
However, even in this case the available data are limited to experimental models and their benefit 







The COVID-19 pandemic is causing numerous deaths worldwide and there are currently no 
vaccines and antivirals directed against the virus. The patient with diabetes and with SARS-COV-2 
infection is a complex patient who needs to be carefully managed clinically, the therapy for diabetes 
cannot be suspended and glycemic normalization must always be sought, however during the 
infection phase some common antidiabetes drugs could represent serious risk factors for 
complications if used incorrectly, for some of them there is also evidence of positive efficacy in the 
COVID-19 positive patient. Clinical data from well-structured epidemiological studies will provide 
the necessary evidence. 
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